KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Vertex Pharmaceuticals (VRTX) over the last 17 years, with Q4 2025 value amounting to $2.0 billion.

  • Vertex Pharmaceuticals' Operating Expenses rose 520.15% to $2.0 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $7.8 billion, marking a year-over-year decrease of 3043.63%. This contributed to the annual value of $7.8 billion for FY2025, which is 3043.63% down from last year.
  • Latest data reveals that Vertex Pharmaceuticals reported Operating Expenses of $2.0 billion as of Q4 2025, which was up 520.15% from $1.9 billion recorded in Q3 2025.
  • Over the past 5 years, Vertex Pharmaceuticals' Operating Expenses peaked at $6.2 billion during Q2 2024, and registered a low of $836.5 million during Q1 2021.
  • Over the past 5 years, Vertex Pharmaceuticals' median Operating Expenses value was $1.5 billion (recorded in 2023), while the average stood at $1.7 billion.
  • In the last 5 years, Vertex Pharmaceuticals' Operating Expenses skyrocketed by 31998.23% in 2024 and then plummeted by 7055.99% in 2025.
  • Vertex Pharmaceuticals' Operating Expenses (Quarter) stood at $1.2 billion in 2021, then rose by 6.22% to $1.3 billion in 2022, then grew by 20.49% to $1.5 billion in 2023, then increased by 23.33% to $1.9 billion in 2024, then increased by 5.2% to $2.0 billion in 2025.
  • Its Operating Expenses was $2.0 billion in Q4 2025, compared to $1.9 billion in Q3 2025 and $1.8 billion in Q2 2025.